Risperidone
In brief
- In our pharmacy, you can buy risperidone without a prescription, with delivery across Australia and discreet packaging; please consult a healthcare professional if you are unsure about suitability.
- Risperidone is used to treat schizophrenia, manic episodes of bipolar disorder, aggression in Alzheimer’s dementia and certain conduct disorders in children; it is an atypical antipsychotic that primarily blocks dopamine D2 and serotonin 5‑HT2A receptors to reduce psychotic and behavioural symptoms.
- Usual oral doses for adults are typically 2–6 mg per day (often started at 1 mg twice daily or 2 mg once daily and titrated); lower doses (e.g. 0.5–2 mg/day) are used in older or frail patients; long‑acting depot doses (Risperdal Consta) are commonly 25–50 mg IM every two weeks and Perseris is given monthly at manufacturer‑specified doses.
- Available as film‑coated tablets, plain tablets, orally disintegrating tablets (ODT), an oral solution (commonly 1 mg/mL), long‑acting intramuscular depot (Risperdal Consta) and extended‑release subcutaneous depot (Perseris).
- Some effects such as sedation or reduced agitation can begin within hours; meaningful reduction in psychotic symptoms may be seen within days to 1–2 weeks, while full clinical benefit can take several weeks.
- For oral dosing the effect is generally maintained over 24 hours with daily dosing; Risperdal Consta injections last about two weeks per dose and Perseris is formulated for monthly administration; the active metabolite also prolongs activity.
- Do not drink alcohol while taking risperidone — alcohol increases sedation and can worsen side effects such as drowsiness, dizziness and impaired coordination.
- The most common side effect is drowsiness (somnolence); other frequent effects include weight gain, increased appetite, extrapyramidal symptoms (e.g. tremor, stiffness), raised prolactin (which can cause sexual dysfunction or breast changes) and orthostatic hypotension.
- Would you like to try risperidone without a prescription?
Safety, Critical Warnings And Patient Protection (Australia Focus)
Basic Risperidone Information
- INN (International Nonproprietary Name): risperidone
- Brand Names Available In Australia: not specified
- ATC Code: N05AX08
- Forms & Dosages: film-coated tablets 0.25–6 mg, plain tablets 0.5–6 mg, orally disintegrating tablets (country-dependent), oral solution commonly 1 mg/mL, long-acting IM depot (Risperdal Consta) 25 mg/37.5 mg/50 mg per injection
- Manufacturers In Australia: not specified
- Registration Status In Australia: not specified
- OTC / Rx Classification: not specified
Worried about serious reactions or how risperidone will affect you or someone you care for?
Seek immediate medical review if there are signs of an allergic reaction such as hives, swelling of the face or throat, or difficulty breathing.
Also seek urgent help for severe sedation, sudden chest pain or shortness of breath, a sudden high fever, or rigid muscles, because these may signal life‑threatening conditions like anaphylaxis, neuroleptic malignant syndrome or severe extrapyramidal reactions.
Older people with dementia‑related psychosis have an increased risk of death when treated with antipsychotics.
Avoid use in this group unless the clinical benefit clearly outweighs the risk and the prescriber documents the rationale.
Notify the prescriber before starting any new medicine, including over‑the‑counter products and herbal supplements such as St John’s wort.
Risperidone may impair alertness, so patients should be warned about driving, work safety and operating machinery under Australian road rules and workplace health‑and‑safety obligations.
Baseline monitoring should include weight, body mass index, blood pressure and heart rate, fasting glucose and lipids, and prolactin if the patient is symptomatic.
Consider an ECG before starting risperidone if there is existing cardiac risk or concurrent use of QT‑prolonging drugs.
Immediate Red Flags:
- Allergic signs: swelling, breathing difficulty, rash.
- Severe sedation or sudden confusion leading to inability to wake.
- High fever with rigidity or altered consciousness.
- Chest pain, palpitations or fainting spells.
- New or worsening movement disorders (sustained facial or tongue movements).
Baseline Monitoring Checklist:
- Weight and BMI.
- Blood pressure and heart rate (include orthostatic readings if elderly).
- Fasting glucose and lipid profile.
- ECG if cardiac risk or co‑medications that prolong QT.
- Prolactin if symptoms such as galactorrhoea or sexual dysfunction appear.
| Check | When |
|---|---|
| Weight/BMI | Baseline, 3 months, then annually |
| BP/Heart Rate | Baseline, early after dose changes, then routine follow‑up |
| Fasting Glucose/Lipids | Baseline, 3 months, then annually (more often if abnormal) |
| ECG | Baseline if cardiac risk; repeat as clinically indicated |
| Prolactin | Check if symptomatic |
Q&A — “Can I Drive After Taking It In Australia?”
Do not drive until you know how risperidone affects you.
If you feel sedated, dizzy, confused or have slowed reaction times, do not drive or operate machinery.
Australian state and territory road rules require that drivers notify their licensing authority if a medical condition or medicine affects safe driving, so check local rules.
Tell your GP and insurer about risperidone use if you are a professional driver or operate heavy machinery.
Plan for transport in the first days after starting or increasing a dose, or after a missed dose where sedation is possible.
If there is any doubt about fitness to drive, discuss timing and any alternative arrangements with the prescriber or pharmacist.
High‑Risk Groups And Monitoring Requirements
Which patients need extra care when prescribed risperidone?
Older adults, especially those with dementia, face higher mortality and falls risk when given antipsychotics.
Start at lower doses in older people, review frequently and favour non‑pharmacological approaches first where possible.
Monitor for orthostatic hypotension and gait instability in this group, and involve carers in safety planning.
Pregnancy and breastfeeding require discussion with the treating obstetrician and psychiatrist because data are limited.
Avoid abrupt cessation in pregnancy because relapse risk must be weighed against potential fetal or neonatal adverse effects such as extrapyramidal signs and feeding difficulties.
If breastfeeding while on risperidone, monitor the infant for sedation and feeding problems.
Patients with chronic medical illnesses need dose adjustments or closer monitoring.
Relevant conditions include hepatic impairment, renal impairment, Parkinson’s disease, cardiovascular disease, diabetes and seizure disorders.
Checklist For Clinicians Before Starting Risperidone:
- Review comorbidities and medications for interactions.
- Perform pregnancy test if relevant.
- Order baseline metabolic panel including fasting glucose and lipids.
- Consider ECG if cardiac history or QT‑prolonging drugs are present.
- Discuss contraception and breastfeeding plans where applicable.
Definition List Of What To Monitor And When:
- Orthostatic blood pressure: baseline and after dose changes in older adults.
- Metabolic panel: baseline, 3 months, then yearly unless abnormalities require more frequent checks.
- Renal and liver function: baseline and periodic checks if impaired.
- Seizure threshold: monitor in patients with epilepsy or on interacting medicines.
Practical Patient Guidance:
Carry an up‑to‑date medicines list that includes risperidone formulation and dose.
Advise carers about urgent signs such as fever, severe rigidity or breathing problems and arrange emergency plans.
Establish regular follow‑up with the GP or psychiatrist every 1–3 months initially or sooner if concerns arise.
Usage Basics — INN, Brand Names And Regulatory Classification (Australia)
People commonly ask what risperidone is called and whether it is regulated in Australia.
INN is risperidone and the drug is classified in the ATC system as N05AX08, under other antipsychotics.
Global brand names listed in regulatory references include Risperdal for the original oral formulation and Risperdal Consta for the long‑acting intramuscular depot.
Other global names referenced are Perseris and various orally disintegrating brands such as Risperdal M‑Tab or Quicklets.
Australian market supplies multiple generics and branded products, although specific Australian brand listings were not specified in the available product data.
TGA approval covers indicated uses consistent with the product information, and clinicians should check the current Product Information (PI) or Consumer Medicines Information (CMI) for brand specifics and consent requirements for depot formulations.
Many formulations of risperidone are PBS‑listed for schizophrenia and bipolar disorder (manic episodes), with restrictions and authority requirements applying to subsidised use.
PBS criteria may restrict who is eligible for subsidy, and prescribers must use authority prescriptions where required.
- Common Australian Brands: not specified in source data; generics labelled risperidone are widely used.
- PBS/Subsidy Checklist: check patient entitlement, obtain authority prescriptions if required, confirm concession card status and document indication on the prescription.
Forms And Dosage Strengths Sold
Which strengths and formulations should pharmacists and prescribers expect to see?
| Pharmaceutical Form | Typical Strengths | Common Clinical Use | PBS Status |
|---|---|---|---|
| Film‑Coated Tablets | 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 6 mg | Core oral form for schizophrenia, bipolar disorder, aggression in dementia and conduct disorder | Often PBS‑listed depending on indication |
| Plain Tablets | 0.5–6 mg | Generic oral formulations for adults and adolescents | Often PBS‑listed |
| Orally Disintegrating Tablets (ODT) | Country‑dependent (branded as M‑Tab/Quicklets) | Useful for dysphagia and adherence support | Varies by brand |
| Oral Solution | Commonly 1 mg/mL | Flexible dosing for paediatrics and titration | Varies by product |
| Long‑Acting IM Depot (Risperdal Consta) | 25 mg, 37.5 mg, 50 mg per injection | Maintenance therapy via deep IM injection, improves adherence | PBS status varies by formulation |
Practical Notes:
- ODTs are useful for patients with swallowing difficulties or poor adherence and are available as Risperdal M‑Tab/Quicklets in some markets.
- Oral solution permits precise paediatric dosing when risperidone oral solution is available.
- LAIs such as Risperdal Consta require trained staff for administration and clinic documentation of batch and expiry.
Dispensing Checklist:
- Verify strength, formulation and administration route at each supply.
- Confirm storage conditions and counselling points with the patient or carer.
- Document any changes in formulation (e.g. switching from tablets to depot).
Abbreviations:
- ODT — Orally Disintegrating Tablet.
- LAI — Long‑Acting Injection.
- IM — Intramuscular.
- SC — Subcutaneous.
Dosing Guide And Adjustments (PBS Reference And Comorbidities)
What starting doses are typical and how are they adjusted?
Adults commonly start at a low dose with gradual titration, for example 1 mg twice daily or 2 mg once daily, increasing according to response and tolerability.
Maintenance dosing varies, commonly 2–6 mg/day for schizophrenia, with lower doses for older adults and for some paediatric indications.
Depot long‑acting injectables follow the product‑specific schedule, for example Risperdal Consta is administered every two weeks with an initial oral overlap per the Product Information.
In renal or hepatic impairment reduce dose and titrate cautiously and consider specialist advice for severe impairment.
Avoid abrupt cessation where possible and taper over weeks to reduce relapse and withdrawal symptoms.
- Typical Starting Ranges: adults 1–2 mg/day initially, titrate to effect; elderly lower starting doses such as 0.5–1 mg/day.
- Maintenance Ranges: commonly 2–6 mg/day for psychotic disorders; paediatric doses are lower and product dependent.
Checklist For Dose Adjustments:
- Consider age, body weight and comorbidities when selecting dose.
- Review interacting medicines that affect CYP2D6 or CYP3A4.
- Monitor side effects during titration and after dose changes.
- Document tapering plans and provide patient instructions for missed doses.
Q&A — “What If I Miss A Dose?”
If a single oral dose is missed and it is only a few hours late, take it as soon as remembered.
If many hours have passed or the next scheduled dose is close, skip the missed dose and resume the usual schedule.
Do not double the next dose to make up for the missed tablet.
For long‑acting injections follow the clinic recall protocol and contact the prescriber promptly if an injection appointment is missed to re‑establish coverage.
If in doubt, ask the dispensing pharmacist or prescriber for specific instructions about missed doses for the formulation supplied.
Drug, Food And Drink Interactions
Which medicines and substances interact importantly with risperidone?
CNS depressants, including alcohol and benzodiazepines, can increase sedation when taken with risperidone and should be avoided or used with caution.
Drugs that prolong the QT interval, such as certain antiarrhythmics and some antidepressants, may increase cardiac risk when combined with risperidone and warrant ECG monitoring.
Potent inhibitors or inducers of CYP2D6 or CYP3A4 can alter risperidone and 9‑hydroxyrisperidone plasma levels, requiring dose adjustment or closer monitoring.
Smoking has indirect effects on antipsychotic metabolism and may influence plasma concentrations, so document smoking status and reassess dose when smoking patterns change.
Complementary medicines such as St John’s wort can alter antipsychotic metabolism and should be declared to the prescriber and pharmacist.
| Drug | Effect | Clinical Action |
|---|---|---|
| Alcohol / Benzodiazepines | Increased sedation | Avoid or use with caution; warn about driving and falls |
| QT‑Prolonging Drugs | Increased cardiac arrhythmia risk | Perform ECG, avoid combinations where possible |
| CYP2D6/CYP3A4 Inhibitors | Higher risperidone levels | Consider dose reduction and monitor for side effects |
| CYP Inducers (e.g. certain anticonvulsants) | Lower risperidone levels | May require dose increase; monitor symptoms |
| St John’s Wort | Alters metabolism | Avoid or discuss with prescriber |
High‑Risk Combinations To Avoid Or Monitor:
- Concurrent CNS depressants with risperidone should be used cautiously to reduce fall and sedation risk.
- Combining multiple antipsychotics or QT‑prolonging agents increases cardiac and movement disorder risks.
- Do not start or stop strong enzyme inhibitors or inducers without reviewing antipsychotic dosing.
Patient Advice At Dispensing:
Avoid alcohol while taking risperidone and report any new prescriptions, over‑the‑counter medicines or herbal products to the pharmacist.
Ask the pharmacist to perform a medicines review if multiple prescribers are involved.
Common And Serious Adverse Effects; Monitoring Schedule
Which side effects should patients and clinicians watch for?
Common adverse effects include sedation, weight gain, daytime somnolence, orthostatic hypotension, akathisia and other extrapyramidal symptoms.
Risperidone can raise prolactin levels, which may cause galactorrhoea or sexual dysfunction in some patients.
Constipation and hypersalivation are other commonly reported effects.
Serious but uncommon effects include neuroleptic malignant syndrome, tardive dyskinesia, severe cardiac events such as QT prolongation, and severe hyperglycaemia including diabetic ketoacidosis.
Recommended Monitoring Schedule:
- Baseline weight/BMI, blood pressure and heart rate, fasting glucose and lipids, and ECG if cardiac risk exists.
- Repeat metabolic tests at 3 months after initiation, then annually if stable or more frequently if abnormalities arise.
- Check prolactin if symptoms suggest hyperprolactinaemia.
| Test | Baseline | 3 Months | 12 Months |
|---|---|---|---|
| Weight/BMI | Yes | Yes | Yes (annually) |
| Fasting Glucose/Lipids | Yes | Yes | Yes |
| BP/Heart Rate | Yes | As indicated | Annually |
| ECG | If cardiac risk | As indicated | As indicated |
| Prolactin | If symptomatic | As indicated | As indicated |
Patient Safety Tips:
Report persistent restlessness, new involuntary facial or tongue movements, fever and muscle stiffness immediately.
Carry an up‑to‑date medicines card and ensure carers know emergency contact details and the signs that require urgent help.
Special Populations — Children, Adolescents, Elderly Dementia, Pregnancy And Breastfeeding
How is risperidone used across different age groups and in pregnancy?
Children and adolescents may be prescribed risperidone for certain conduct disorders and irritability associated with autism under paediatric supervision.
Use lower starting doses in younger patients and monitor growth, weight and metabolic parameters closely.
Paediatric formulations such as the oral solution or ODT facilitate accurate dosing.
Elderly patients with dementia carry increased mortality risk; antipsychotics are only appropriate when behaviour presents immediate risk and non‑pharmacological measures have failed.
Use the lowest effective dose and review the need for continuation frequently, ideally within weeks of starting.
Pregnancy and Breastfeeding:
Available data are limited, so discuss risks with the obstetrician and treating psychiatrist.
If risperidone is continued in pregnancy, monitor the neonate for extrapyramidal signs and feeding difficulties after birth.
If breastfeeding, observe the infant for sedation or feeding problems and consider specialist input.
- Age‑Specific Cautions: monitor metabolic and growth effects in children, orthostatic hypotension and falls in the elderly.
- Consent And Referral Checklist: document informed consent, specify monitoring plan and consider specialist referral for paediatrics or pregnancy.
Depot And Long‑Acting Injections — Adherence And Administration Logistics
Why consider long‑acting injectables (LAIs) and what do clinics need to provide?
LAIs such as Risperdal Consta can improve adherence and reduce relapse risk when used correctly.
Risperdal Consta is given as a deep intramuscular injection every two weeks and commonly comes in 25 mg, 37.5 mg and 50 mg strengths with an oral overlap period per the product information.
Perseris is an extended‑release subcutaneous option referenced in international lists but check current TGA status before use.
Administration Requirements:
- Trained staff for IM or SC injection, injection site rotation and appropriate documentation of batch and expiry.
- Cold‑chain handling may be required for certain depot products, so follow PI storage and transport instructions.
| Product | Route | Dosing Interval | Advantages | PBS Status |
|---|---|---|---|---|
| Risperdal Consta | IM | Every 2 weeks | Steady plasma levels, improved adherence | Varies by indication |
| Perseris | SC | Monthly (where approved) | Monthly dosing option | Check TGA status |
Clinic Setup Checklist:
- Obtain informed consent and document it in the patient record.
- Ensure appropriate storage and an emergency kit for anaphylaxis.
- Schedule follow‑up and injection reminders to avoid missed doses and relapses.
Access, Purchase Options And Telehealth In Australia
Where can patients get risperidone and how does telehealth help?
Community pharmacy chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart, as well as independent pharmacies, dispense risperidone and commonly carry generics.
Many online pharmacies and telehealth services accept e‑prescriptions and supply to Australian addresses, but verify prescription validity and pharmacy accreditation.
Rural patients may need extra coordination for depot clinics or mail delivery, and injectables should have cold‑chain protection where required.
PBS and subsidised access depend on authority requirements and prescriber paperwork.
In our online pharmacy, risperidone is available without a prescription, with discreet delivery to Australia in 9‑21 days.
- Patient Checklist: bring prescription or e‑script, PBS concession card if eligible, list of current medicines and allergy information.
- Access Routes: community pharmacy, hospital outpatient clinic, mental health clinic and accredited online pharmacy with e‑prescriptions.
Price Comparison And PBS Subsidy Practicalities
How much will risperidone cost and how can patients save on price?
Price depends on brand versus generic, dispensing fees, PBS concession status and whether an authority is required for a subsidised item.
Depot administration may incur additional clinic fees for injection services even when the medicine is PBS‑subsidised.
| Pharmacy/Source | Typical Cash Price | PBS Subsidy Status | Prescription Requirement | Notes |
|---|---|---|---|---|
| Community Pharmacy (Chain) | Varies | Some formulations PBS‑listed | Prescription required | Generic substitution commonly available |
| Independent Pharmacy | Varies | Some formulations PBS‑listed | Prescription required | May order specific brands on request |
| Online Pharmacy | Varies | Varies | Prescription or e‑script required | Check accreditation and delivery times |
| Hospital Outpatient Clinic | May be subsidised | Often PBS or hospital supply | Prescription by hospital clinician | Depot administration usually available |
Steps To Access PBS:
- Obtain any required authority prescription from the prescriber.
- Present concession card or Medicare details at the pharmacy.
- Ask the pharmacist about generic alternatives to reduce cost.
- Track safety net thresholds if multiple scripts are needed.
Rural Considerations:
Telehealth e‑scripts and mail delivery can reduce travel for rural patients, but confirm storage instructions for injectables and expected delivery times with the dispensing pharmacy.
Mechanism Of Action And Pharmacology
How does risperidone work and what does that mean clinically?
Risperidone is an atypical antipsychotic that antagonises dopamine D2 receptors and serotonin 5‑HT2A receptors, which underpins its antipsychotic and mood‑stabilising effects.
The active metabolite 9‑hydroxyrisperidone contributes to clinical activity.
Risperidone is classified in the pharmacotherapeutic group “other antipsychotics” with ATC code N05AX08, reflecting its placement among atypical agents.
Pharmacokinetics include oral absorption and hepatic metabolism involving CYP pathways, while long‑acting injectables provide sustained release over weeks.
Clinical relevance of the mechanism includes prolactin elevation due to dopamine blockade and a lower risk of extrapyramidal symptoms than older typical antipsychotics because of combined dopamine and serotonin receptor effects.
- ATC Breakdown: N / N05 / N05A / N05AX / N05AX08.
- Mechanism‑Side Effect Links: D2 blockade → hyperprolactinaemia; 5‑HT2A antagonism → reduced EPS risk compared with typical agents.
Indications (TGA/PBS) And Off‑Label Uses In Australian Practice
What is risperidone approved for and where is it sometimes used off‑label?
TGA and PBS commonly list risperidone for schizophrenia, acute manic episodes of bipolar disorder and certain aggressive behaviours in dementia and conduct disorders in children and adolescents.
Off‑label uses described in practice include treatment‑resistant agitation, augmentation in mood disorders and some neuropsychiatric symptoms, but these should be used only with specialist oversight and documented rationale.
Prescribers must ensure informed consent, document the indication and planned duration, and maintain a deprescribing strategy for off‑label use.
- Approved Indications: schizophrenia, mania (bipolar disorder), certain dementia‑related aggression, some paediatric conduct disorders.
- Common Off‑Label Indications: augmentation in mood disorders, refractory agitation under specialist direction.
Patient Information:
Explain expected benefits and the typical timeline for response, which may be days to weeks for agitation and several weeks for psychotic symptoms.
Advise when to seek urgent help, such as for sudden fever, severe stiffness or breathing problems.
Alternatives And Comparison Matrix (PBS‑Listed Antipsychotics)
What are alternative antipsychotics and how do they compare with risperidone?
Common PBS alternatives include olanzapine, quetiapine, aripiprazole, paliperidone (an LAI option) and haloperidol for typical antipsychotic needs.
Each alternative differs in metabolic side‑effect burden, extrapyramidal symptom risk and sedation profile.
| Drug | Typical Dose Range | Key Pros | Key Cons | PBS Status |
|---|---|---|---|---|
| Olanzapine | 5–20 mg/day | Effective for psychosis and mania | High metabolic risk | PBS‑listed for specific indications |
| Quetiapine | 50–800 mg/day (varies) | Less EPS; useful for bipolar depression | Somnolence, metabolic effects | PBS‑listed |
| Aripiprazole | 2–30 mg/day | Lower prolactin effects, partial D2 agonist | Akathisia in some patients | PBS‑listed |
| Paliperidone | Oral and LAI options | LAI available for maintenance | Prolactin elevation | PBS‑listed options exist |
| Haloperidol | 0.5–10 mg/day | Potent antipsychotic | Higher EPS risk | PBS‑listed historically |
Switching Considerations:
- Clarify the reason for switching such as side effects or inadequate efficacy.
- Plan washout or cross‑titration to reduce withdrawal and adverse effects.
- Monitor metabolic parameters and extrapyramidal symptoms closely during the transition.
Non‑Pharmacological Options:
Prioritise psychosocial interventions, cognitive behavioural therapy and environmental adjustments for agitation in dementia before antipsychotic use where possible.
Practical Counselling Points, Storage, Handling And Pharmacy Advice
What should pharmacists tell patients at dispensing?
Advise patients to take risperidone exactly as prescribed and to avoid alcohol while taking it.
Warn about signs of tardive movements, severe sedation or cardiovascular symptoms and instruct patients to seek urgent help if these occur.
Recommend carrying an up‑to‑date medicines list and informing all prescribers and pharmacists about risperidone use.
Storage Advice For Australian Homes:
Store oral formulations below 25°C and protect them from heat and humidity; avoid leaving medicines in hot cars or direct sunlight.
Check manufacturer instructions for the oral solution and discard after the specified expiry once opened.
Pharmacy Handling For Depots:
Depot products may require refrigeration or specific storage and cold‑chain protocols; follow the Product Information and document batch numbers and expiry at dispensing and in clinic records.
- Patient Checklist: storage instructions, missed dose actions, emergency contacts and scheduled reviews.
- Pharmacist Checklist: explain baseline checks and monitoring plan, obtain consent for LAI administration and confirm injection protocols.
Documentation:
Provide the CMI and a written monitoring schedule, arrange follow‑up with GP or psychiatrist and liaise with community mental health services when relevant.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 9–14 days |
| Melbourne | Victoria | 9–14 days |
| Brisbane | Queensland | 9–14 days |
| Perth | Western Australia | 9–14 days |
| Adelaide | South Australia | 9–14 days |
| Canberra | Australian Capital Territory | 9–14 days |
| Hobart | Tasmania | 9–14 days |
| Darwin | Northern Territory | 9–14 days |
| Gold Coast | Queensland | 9–14 days |
| Newcastle | New South Wales | 9–14 days |
| Wollongong | New South Wales | 9–14 days |
| Geelong | Victoria | 9–14 days |